- Home
- CVBF vs CPRX Comparison
CVBF vs CPRX Comparison
Compare CVBF & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CVBF | CPRX |
|---|---|---|
| Founded | 1974 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.9B |
| IPO Year | 2009 | 2006 |
Fundamental Metrics
Financial Performance| Metric | CVBF | CPRX |
|---|---|---|
| Price | $20.24 | $25.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $24.17 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 1.2M | 988.7K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.90% | N/A |
| EPS Growth | 5.56 | ★ 28.24 |
| EPS | 1.52 | ★ 1.68 |
| Revenue | N/A | ★ $119,072,803.00 |
| Revenue This Year | $21.47 | $9.20 |
| Revenue Next Year | $15.21 | $10.51 |
| P/E Ratio | ★ $13.48 | $15.60 |
| Revenue Growth | N/A | ★ 16.39 |
| 52 Week Low | $17.45 | $19.05 |
| 52 Week High | $21.48 | $26.56 |
Technical Indicators
Market Signals| Indicator | CVBF | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 59.13 | 60.13 |
| Support Level | $19.18 | $22.24 |
| Resistance Level | $20.62 | N/A |
| Average True Range (ATR) | 0.44 | 0.69 |
| MACD | 0.13 | 0.18 |
| Stochastic Oscillator | 72.22 | 78.92 |
Price Performance
Historical ComparisonAbout CVBF CVB Financial Corporation
CVB Financial Corp is the holding company for Citizens Business Bank. Citizens Business Bank offers banking, lending, and investing services. It provides a full complement of lending products, including commercial, agribusiness, consumer, SBA, real estate, and construction loans, as well as equipment and vehicle leasing. Commercial products include lines of credit and other working capital financing, accounts receivable lending and letters of credit. It is a community bank with one reportable operating segment.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.